<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Using second-site homologous recombination, Epstein-Barr virus (EBV) recombinants were constructed which carry an LMP2A mutation terminating translation at codon 19 </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the absence of LMP2A or LMP2A cross-reactive protein, the recombinants were able to initiate and maintain primary B-lymphocyte growth transformation in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>EBNA1, EBNA2, and LMP1 expression was unaffected by the LMP2A mutation </plain></SENT>
<SENT sid="3" pm="."><plain>The LMP2A mutant recombinant EBV-infected lymphoblastoid cell lines (LCLs) were identical to <z:mp ids='MP_0002169'>wild-type</z:mp> recombinant EBV-infected control LCLs with respect to initial outgrowth, subsequent growth, sensitivity to limiting cell dilution, sensitivity to low serum, and growth in soft <z:chebi fb="2" ids="2511">agarose</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The permissivity of LCLs for lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and virus replication was also unaffected by the LMP2A mutation </plain></SENT>
</text></document>